Curis (NASDAQ: CRIS) is one of 187 public companies in the “Biotechnology & Medical Research” industry, but how does it contrast to its peers? We will compare Curis to related companies based on the strength of its institutional ownership, valuation, risk, dividends, earnings, profitability and analyst recommendations.
This table compares Curis and its peers’ net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
This is a summary of recent ratings and target prices for Curis and its peers, as provided by MarketBeat.com.
||Strong Buy Ratings
Curis presently has a consensus target price of $6.50, indicating a potential upside of 692.68%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 18.32%. Given Curis’ stronger consensus rating and higher probable upside, equities analysts clearly believe Curis is more favorable than its peers.
Valuation & Earnings
This table compares Curis and its peers gross revenue, earnings per share (EPS) and valuation.
Curis’ peers have higher revenue and earnings than Curis. Curis is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Volatility and Risk
Curis has a beta of 1.62, meaning that its stock price is 62% more volatile than the S&P 500. Comparatively, Curis’ peers have a beta of 1.53, meaning that their average stock price is 53% more volatile than the S&P 500.
Institutional & Insider Ownership
55.2% of Curis shares are owned by institutional investors. Comparatively, 49.3% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 4.1% of Curis shares are owned by company insiders. Comparatively, 14.7% of shares of all “Biotechnology & Medical Research” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Curis beats its peers on 7 of the 12 factors compared.
Curis, Inc. is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company’s drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes. CA-170 is an oral small molecule drug candidate that is designed to selectively target programmed death ligand-1 (PDL1) and V-domain Ig suppressor of T-cell activation (VISTA) immune checkpoint proteins, both of which independently function as negative regulators of immune activation. CA-4948 is an oral small molecule drug candidate that is designed to inhibit the Interleukin-1 receptor-associated kinase 4 (IRAK4) kinase, which is a transducer of toll-like receptor or certain interleukin receptor signaling pathways.
Receive News & Ratings for Curis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.